Join us at the Atlanta Precision Oncology Symposium

February 5th, 2022, 7:40–8:10 AM EST

Join Dr. Joshua Routh at APOS for a Sponsored Breakfast Symposium: Next-Generation Sequencing on Small Tumor Specimens and/or Low Tumor Content Samples Using Novel Platforms.

RxPONDER Data Published!

Read the press release to learn more about how the newly published RxPONDER data helps inform treatment for node positive patients.

Redesigned Clinically Low-Risk Report

Oncotype DX Genomic Prostate Score Assay

Introducing the newly re-designed Oncotype DX GPS assay report for clinically low-risk prostate cancer patients.

20-Year Outcomes: Adverse Pathology

Oncotype DX Genomic Prostate Score Assay

New follow-up data suggests adverse pathology as a predictor of prostate cancer specific mortality and metastasis for clinically low-risk prostate cancer patients for up to 20 years after diagnosis.
Making cancer care smarter.™